Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, novembre 17
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
LB Pharmaceuticals Inc
LBRX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$42.99
-0.02
-0.05%
À la clôture: Nov 13, 4:00 PM EST
$42.99
-0.02
-0.05%
Pré-ouverture: 7:56 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
LB Pharmaceuticals Financials
LB Pharmaceuticals (LBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
LB Pharmaceuticals On Track For Phase 3 NOVA-2 LB-102 Schizophrenia Topline Data In 1H27; Cash $403.8M Funds Operations Beyond Q2 2029
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q3 GAAP EPS $(1.79) vs $(0.61) YoY
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.75) by 10.67 percent. This is a 95.47 percent increase over losses of $(14.79) per share
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share
Benzinga Newsdesk
PRO
LB Pharmaceuticals Q3 EPS $(0.61) Beats $(0.63) Estimate
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.63) by 3.17 percent. This is a 98.46 percent increase over losses of $(39.49) per share
Benzinga Newsdesk